Table 5.
Immunohistochemical profile, tumor classification, and therapeutic intervention.
| Therapeutic interventions∗ | p value | ||||
|---|---|---|---|---|---|
| Only surgery (%) | Surgery and medical treatment (%) | Surgery and radiotherapy (%) | Surgery, medical treatment, and radiotherapy (%) | ||
| Patients n (%) | 11 (22) | 20 (40) | 11 (22) | 8 (16) | |
|
| |||||
| Immunohistochemistry | |||||
| Hormone expression | 0.0186 | ||||
| GH (n = 14) | 1 (7) [−2] | 9 (64) [2] | 0 (0.00) [−2] | 4 (29) [1] | |
| PRL (n = 8) | 1 (13) [−1] | 6 (74) [2] | 0 (0.00) [−2] | 1 (13) [0] | |
| ACTH (n = 3) | 1 (33) [0] | 0 (0) [−1] | 1 (33) [0] | 1 (33) [1] | |
| LH/FSH (n = 7) | 2 (29) [0] | 2 (29) [−1] | 3 (42) [1] | 0 (0) [−1] | |
| Null cell (n = 18) | 6 (33) [1] | 3 (17) [−2] | 7 (39) [2] | 2 (11) [−1] | |
| Tumor markers | |||||
| p53 | 0.1527 | ||||
| <3+ | 4 (21) | 4 (21) | 7 (37) | 4 (21) | |
| ≥3+ | 7 (24) | 14 (48) | 4 (14) | 4 (14) | |
| Ki-67 | 0.0110 | ||||
| <2+ | 10 (31) [2] | 8 (25) [−2] | 10 (31) [2] | 5 (13) [−1] | |
| ≥2+ | 1 (6) [−2] | 10 (63) [2] | 1 (6) [−2] | 4 (25) [1] | |
| c-erbB2 | 0.3018 | ||||
| <2+ | 4 (27) | 8 (53) | 2 (13) | 1 (7) | |
| ≥2+ | 7 (23) | 9 (29) | 9 (29) | 6 (19) | |
|
| |||||
| Clinicopathological classification | 0.6858 | ||||
| 1A | 1 (50) | 0 (0) | 0 (0) | 1 (50) | |
| 1B | 0 (0) | 0 (0) | 1 (100) | 0 (0) | |
| 2A | 4 (19) | 9 (43) | 5 (24) | 3 (14) | |
| 2B | 6 (23) | 11 (43) | 5 (19) | 4 (15) | |
∗Values expressed as frequency (%) and [Pearson residual].
p value computed using Pearson's chi-square test.